drugset / Trial / NCT07010107
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
Timeline
- Start
- 2025-07-30
- Primary completion
- 2026-04
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anaprazole | Other / unclassified | 60 mg | Oral |
| Comparator | Rabeprazole | Small molecule | 20 mg | Oral |